<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00224640</url>
  </required_header>
  <id_info>
    <org_study_id>P041201</org_study_id>
    <secondary_id>PCR 05001</secondary_id>
    <nct_id>NCT00224640</nct_id>
  </id_info>
  <brief_title>Iron-Chelating Therapy and Friedreich Ataxia</brief_title>
  <official_title>Effect of Iron-Chelating Therapy in Friedreich Ataxia. Study Phase I/II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Friedreich ataxia, an autosomal recessive condition, ascribed to frataxin gene expansion, has
      been shown to result from an iron- induced injury to the mitochondrial respiratory chain.
      Buffering free radicals with short-chain quinones (Idebenone) protects the patients against
      cardiomyopathy but not CNS involvement. Removing CNS iron should limit the impact of the
      neurological symptoms of the disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current clinical trial is a monocentric open phase1-2 trial in the context of rare
      diseases framework, aimed to the goal of defining the tolerance/efficacy of the treatment.

      Inclusion criteria: minimum age: 13 years Follow up in the Dept of Genetics, Hospital
      Necker-Enfants Malades, Paris, France
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>assessment of iron overload at TO and month2 by imagery</measure>
    <time_frame>at months :0, 1 ,2 ,4 ,6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical (monthly) and biological parameter follow- up ( blood count,</measure>
    <time_frame>weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma iron, ferritin, transferrin and liver enzymes)</measure>
    <time_frame>every months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Friedreich Ataxia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Iron chelating intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron chelating intervention</intervention_name>
    <description>Iron chelating intervention</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Minimum age: 13 years

          2. Molecular confirmation of frataxin gene mutation

          3. Iron overload evaluation

          4. Presence of lactate

          5. Echography response to Idebenone treatment

          6. Urinary test of pregnancy for girls

          7. Sexual abstinence for men

          8. Information consent

        Exclusion Criteria:

          1. No disturbance of iron metabolism

          2. No response to Idebenone

          3. Friedreich not confirmed

          4. Polynuclear neutrophils &lt;2 x 109/L or hemoglobin &lt; 8g/dL

          5. No participation to other trial

          6. Doubt regarding the compliance of the patient to protocol

          7. Impossibility to undergo X-ray examination or presence of iron material in the
             backbone

          8. Pregnant women

          9. Absence of social insurance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnold MUNNICH, Pr,MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Necker Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2005</study_first_posted>
  <last_update_submitted>March 3, 2009</last_update_submitted>
  <last_update_submitted_qc>March 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Amel Ouslimany</name_title>
    <organization>Department Clinical Research of Developpement</organization>
  </responsible_party>
  <keyword>Iron-chelating treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Iron Chelating Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

